Shuttle Pharma's CEO will discuss 2025 plans at Lytham Partners Investor Healthcare Summit on January 13, 2025.
Quiver AI Summary
Shuttle Pharmaceuticals Holdings, Inc. announced that its CEO, Dr. Anatoly Dritschilo, will participate in a webcast fireside chat at the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025, at 3:30 p.m. Eastern time. During the chat, Dr. Dritschilo will update attendees on the company's plans for 2025, focusing on the progress of its Phase 2 clinical trial of Ropidoxuridine for glioblastoma patients and developments related to its Shuttle Diagnostics subsidiary's PC-RAD test for prostate cancer. Interested parties can access the live event and its replay through designated links. Shuttle Pharmaceuticals aims to enhance cancer treatment outcomes and reduce side effects of radiation therapy, positioning itself as a leader in this area since its founding in 2012.
Potential Positives
- CEO Anatoly Dritschilo will participate in a prominent investor healthcare summit, which highlights the company's visibility and engagement with investors.
- The discussion will focus on significant advancements in the Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma patients, indicating ongoing progress in critical research.
- Shuttle Diagnostics is expected to present developments in the PC-RAD test for predicting outcomes after radiation therapy, showing innovation in cancer treatment diagnostics.
- The company aims to improve the lives of cancer patients by developing therapies that maximize radiation therapy effectiveness, aligning with a strong mission in oncology care.
Potential Negatives
- The company is in the discovery and development stage, indicating that it has yet to bring products to market, which may raise concerns about its viability and growth potential.
- Forward-looking statements in the release warn of uncertainties related to the success and timelines of clinical trials, which can impact investor confidence.
- The focus on a niche area of cancer treatment may limit the company's market appeal and potential for financial success compared to broader pharmaceutical companies.
FAQ
What is the purpose of the upcoming fireside chat?
The fireside chat will cover Shuttle Pharma's plans for 2025 and updates on their clinical trials.
When will the fireside chat take place?
The fireside chat is scheduled for January 13, 2025, at 3:30 p.m. Eastern Time.
How can I access the webcast of the event?
The webcast can be accessed through the Lytham Partners conference homepage or directly via their provided link.
What topics will Dr. Dritschilo discuss during the chat?
Dr. Dritschilo will discuss the Phase 2 Clinical Trial of Ropidoxuridine and updates on Shuttle Diagnostics' PC-RAD test.
Where can I find more information about Shuttle Pharmaceuticals?
For more information, visit Shuttle Pharmaceuticals' official website at www.shuttlepharma.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SHPH Hedge Fund Activity
We have seen 0 institutional investors add shares of $SHPH stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIRTU FINANCIAL LLC removed 1,593 shares (-100.0%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
The fireside chat will take place at 3:30 p.m. Eastern time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at
https://lythampartners.com/health2025/
or directly at
https://lythampartners.com/health2025/shph
. A replay of the fireside chat will also be available through the same links.
1x1 investor meetings will be available after the event upon request by contacting your Lytham representative at
1x1@lythampartners.com
.
Dr. Dritschilo will discuss the Company’s plans for 2025. Topics are expected to include the progress being made in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma. The ongoing trial of the Company’s lead candidate is currently enrolling patients at six nationally recognized cancer centers to treat patients with IDH wild-type, methylation negative glioblastoma, the target of the clinical trial. Further, Dr. Dritschilo is expected to discuss recent developments being made within its Shuttle Diagnostics subsidiary focused on its PC-RAD test for predicting outcomes following radiation therapy for localized prostate cancer, as well as its ligand to the prostate-specific membrane antigen (PSMA) as a potential diagnostic and therapeutic, or theranostic, molecule.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at
www.shuttlepharma.com
.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including our expectations regarding the success and/or completion of our pre-clinical research; our success in completing any newly initiated clinical trials, commence new trials and obtain regulatory approval following such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2023, as amended, filed with the SEC on September 4, 2024, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
